{"id":65221,"date":"2026-05-13T23:32:00","date_gmt":"2026-05-13T15:32:00","guid":{"rendered":"https:\/\/flcube.com\/?p=65221"},"modified":"2026-05-13T23:32:03","modified_gmt":"2026-05-13T15:32:03","slug":"shenzhen-weiguang-biological-to-raise-rmb-1-5b-in-private-placement-to-fund-smart-industrial-base-expansion","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=65221","title":{"rendered":"Shenzhen Weiguang Biological to Raise RMB 1.5B in Private Placement to Fund Smart Industrial Base Expansion"},"content":{"rendered":"\n<p><strong>Shenzhen Weiguang Biological Products Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/002880:SHE\">SHE: 002880<\/a>), a China-based blood products manufacturer, announced plans to issue <strong>A-shares to specific targeted investors<\/strong> in a private placement aiming to raise <strong>RMB 1.5 billion<\/strong> (USD 220 million) to address capacity constraints and support new product industrialization.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-capital-raise-overview\">Capital Raise Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Shenzhen Weiguang Biological Products Co., Ltd. (SHE: 002880)<\/td><\/tr><tr><td><strong>Fundraising Method<\/strong><\/td><td>Private placement of A-shares to targeted investors<\/td><\/tr><tr><td><strong>Total Amount<\/strong><\/td><td>RMB 1.5 billion (USD 220 million)<\/td><\/tr><tr><td><strong>Net Proceeds Allocation<\/strong><\/td><td>RMB 1.2 billion for smart industrial base project + RMB 300 million for working capital<\/td><\/tr><tr><td><strong>Current Capacity<\/strong><\/td><td>650 tons annual plasma processing capacity<\/td><\/tr><tr><td><strong>Facility Status<\/strong><\/td><td>Existing production line completed in 2013<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-investment-rationale\">Strategic Investment Rationale<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-capacity-constraint-drivers\">Capacity Constraint Drivers<\/h3>\n\n\n\n<p>The company&#8217;s existing infrastructure can no longer support its growth trajectory:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Aging facility<\/strong>: Current production line operational since <strong>2013<\/strong> (13 years old)<\/li>\n\n\n\n<li><strong>Capacity limitation<\/strong>: <strong>650 tons annual plasma processing capacity<\/strong> insufficient for new product pipeline<\/li>\n\n\n\n<li><strong>Industrialization gap<\/strong>: Inability to scale new blood product development due to physical constraints<\/li>\n\n\n\n<li><strong>Market demand<\/strong>: Growing Chinese blood products market requiring expanded manufacturing footprint<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-smart-industrial-base-project\">Smart Industrial Base Project<\/h3>\n\n\n\n<p>The <strong>RMB 1.2 billion investment<\/strong> will fund a next-generation manufacturing facility featuring:<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Feature<\/th><th>Strategic Benefit<\/th><\/tr><\/thead><tbody><tr><td><strong>Expanded capacity<\/strong><\/td><td>Increased plasma processing capability to meet growing demand<\/td><\/tr><tr><td><strong>Smart manufacturing<\/strong><\/td><td>Advanced automation and digital integration for quality consistency<\/td><\/tr><tr><td><strong>New product support<\/strong><\/td><td>Infrastructure optimized for next-generation blood product development<\/td><\/tr><tr><td><strong>Regulatory compliance<\/strong><\/td><td>State-of-the-art GMP standards aligned with international requirements<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financial-allocation-strategy\">Financial Allocation Strategy<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-proceeds-utilization-breakdown\">Proceeds Utilization Breakdown<\/h3>\n\n\n\n<p>After deducting issuance expenses, net proceeds will be allocated as follows:<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Purpose<\/th><th>Amount<\/th><th>Strategic Rationale<\/th><\/tr><\/thead><tbody><tr><td><strong>Smart Industrial Base Project<\/strong><\/td><td>RMB 1.2 billion (80%)<\/td><td>Address core capacity constraints and enable new product industrialization<\/td><\/tr><tr><td><strong>Working Capital Supplement<\/strong><\/td><td>RMB 300 million (20%)<\/td><td>Support operational expansion and maintain financial flexibility during transition<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-targeted-investor-approach\">Targeted Investor Approach<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Strategic investors<\/strong>: Focus on institutional investors with healthcare sector expertise<\/li>\n\n\n\n<li><strong>Long-term alignment<\/strong>: Private placement structure ensures investor commitment to company vision<\/li>\n\n\n\n<li><strong>Market conditions<\/strong>: Timing leverages strong demand for Chinese biopharmaceutical manufacturing assets<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context-amp-industry-dynamics\">Market Context &amp; Industry Dynamics<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-chinese-blood-products-market\">Chinese Blood Products Market<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Supply-demand imbalance<\/strong>: Chronic shortage of blood products in China due to limited plasma collection infrastructure<\/li>\n\n\n\n<li><strong>Regulatory environment<\/strong>: Strict licensing requirements create high barriers to entry and protect incumbents<\/li>\n\n\n\n<li><strong>Growth trajectory<\/strong>: Market projected to grow at <strong>12-15% CAGR<\/strong> through 2030 driven by aging population and improved healthcare access<\/li>\n\n\n\n<li><strong>Import substitution<\/strong>: Government policies favor domestic manufacturers over imported blood products<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-competitive-positioning\">Competitive Positioning<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Established player<\/strong>: Weiguang Bio represents one of China&#8217;s licensed blood products manufacturers<\/li>\n\n\n\n<li><strong>Capacity expansion race<\/strong>: Multiple competitors also investing in facility upgrades and capacity increases<\/li>\n\n\n\n<li><strong>Technology leadership<\/strong>: Smart manufacturing approach positions company at forefront of industry modernization<\/li>\n\n\n\n<li><strong>Vertical integration<\/strong>: Enhanced capacity supports broader product portfolio development<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications\">Strategic Implications<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-operational-impact\">Operational Impact<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Production scalability<\/strong>: New facility will enable significant increase in output volumes<\/li>\n\n\n\n<li><strong>Product diversification<\/strong>: Infrastructure supports development of higher-value plasma-derived products<\/li>\n\n\n\n<li><strong>Quality enhancement<\/strong>: Advanced manufacturing systems improve product consistency and safety profiles<\/li>\n\n\n\n<li><strong>Cost optimization<\/strong>: Economies of scale and automation reduce per-unit production costs<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-financial-considerations\">Financial Considerations<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Capital efficiency<\/strong>: Targeted private placement minimizes dilution compared to public offering<\/li>\n\n\n\n<li><strong>Growth funding<\/strong>: Addresses critical infrastructure needs without excessive debt burden<\/li>\n\n\n\n<li><strong>Return on investment<\/strong>: Expanded capacity expected to generate significant revenue growth from new and existing products<\/li>\n<\/ul>\n\n\n\n<p>The capital raise represents a <strong>strategic response<\/strong> to the evolving Chinese blood products landscape, where capacity expansion and technological modernization are essential for maintaining competitive advantage in a high-growth, regulated market.<\/p>\n\n\n\n<p><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding capital raising, facility construction, and market expansion. Actual results may differ due to risks including regulatory approvals, construction delays, and market dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/\u536b\u5149\u751f\u7269\uff1a\u6df1\u5733\u5e02\u536b\u5149\u751f\u7269\u5236\u54c1\u80a1\u4efd\u6709\u9650\u516c\u53f8\u5411\u7279\u5b9a\u5bf9\u8c61\u53d1\u884cA\u80a1\u80a1\u7968\u52df\u96c6\u8bf4\u660e\u4e66\uff08\u6ce8\u518c\u7a3f\uff092025\u5e74\u5e74\u62a5\u66f4\u65b0\u7a3f.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of \u536b\u5149\u751f\u7269\uff1a\u6df1\u5733\u5e02\u536b\u5149\u751f\u7269\u5236\u54c1\u80a1\u4efd\u6709\u9650\u516c\u53f8\u5411\u7279\u5b9a\u5bf9\u8c61\u53d1\u884cA\u80a1\u80a1\u7968\u52df\u96c6\u8bf4\u660e\u4e66\uff08\u6ce8\u518c\u7a3f\uff09(2025\u5e74\u5e74\u62a5\u66f4\u65b0\u7a3f).\"><\/object><a id=\"wp-block-file--media-15016c8a-fce4-463a-9bed-f36419ffb370\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/\u536b\u5149\u751f\u7269\uff1a\u6df1\u5733\u5e02\u536b\u5149\u751f\u7269\u5236\u54c1\u80a1\u4efd\u6709\u9650\u516c\u53f8\u5411\u7279\u5b9a\u5bf9\u8c61\u53d1\u884cA\u80a1\u80a1\u7968\u52df\u96c6\u8bf4\u660e\u4e66\uff08\u6ce8\u518c\u7a3f\uff092025\u5e74\u5e74\u62a5\u66f4\u65b0\u7a3f.pdf\">\u536b\u5149\u751f\u7269\uff1a\u6df1\u5733\u5e02\u536b\u5149\u751f\u7269\u5236\u54c1\u80a1\u4efd\u6709\u9650\u516c\u53f8\u5411\u7279\u5b9a\u5bf9\u8c61\u53d1\u884cA\u80a1\u80a1\u7968\u52df\u96c6\u8bf4\u660e\u4e66\uff08\u6ce8\u518c\u7a3f\uff09(2025\u5e74\u5e74\u62a5\u66f4\u65b0\u7a3f)<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/\u536b\u5149\u751f\u7269\uff1a\u6df1\u5733\u5e02\u536b\u5149\u751f\u7269\u5236\u54c1\u80a1\u4efd\u6709\u9650\u516c\u53f8\u5411\u7279\u5b9a\u5bf9\u8c61\u53d1\u884cA\u80a1\u80a1\u7968\u52df\u96c6\u8bf4\u660e\u4e66\uff08\u6ce8\u518c\u7a3f\uff092025\u5e74\u5e74\u62a5\u66f4\u65b0\u7a3f.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-15016c8a-fce4-463a-9bed-f36419ffb370\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Shenzhen Weiguang Biological Products Co., Ltd. (SHE: 002880), a China-based blood products manufacturer, announced plans&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[2150,2151],"class_list":["post-65221","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-she-002880","tag-weiguang-biological-products"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.6) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Shenzhen Weiguang Biological to Raise RMB 1.5B in Private Placement to Fund Smart Industrial Base Expansion - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Shenzhen Weiguang Biological Products Co., Ltd. (SHE: 002880), a China-based blood products manufacturer, announced plans to issue A-shares to specific targeted investors in a private placement aiming to raise RMB 1.5 billion (USD 220 million) to address capacity constraints and support new product industrialization.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=65221\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Shenzhen Weiguang Biological to Raise RMB 1.5B in Private Placement to Fund Smart Industrial Base Expansion\" \/>\n<meta property=\"og:description\" content=\"Shenzhen Weiguang Biological Products Co., Ltd. (SHE: 002880), a China-based blood products manufacturer, announced plans to issue A-shares to specific targeted investors in a private placement aiming to raise RMB 1.5 billion (USD 220 million) to address capacity constraints and support new product industrialization.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=65221\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-13T15:32:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-13T15:32:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65221#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65221\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Shenzhen Weiguang Biological to Raise RMB 1.5B in Private Placement to Fund Smart Industrial Base Expansion\",\"datePublished\":\"2026-05-13T15:32:00+00:00\",\"dateModified\":\"2026-05-13T15:32:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65221\"},\"wordCount\":586,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"SHE: 002880\",\"Weiguang Biological Products\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=65221#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65221\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=65221\",\"name\":\"Shenzhen Weiguang Biological to Raise RMB 1.5B in Private Placement to Fund Smart Industrial Base Expansion - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-05-13T15:32:00+00:00\",\"dateModified\":\"2026-05-13T15:32:03+00:00\",\"description\":\"Shenzhen Weiguang Biological Products Co., Ltd. (SHE: 002880), a China-based blood products manufacturer, announced plans to issue A-shares to specific targeted investors in a private placement aiming to raise RMB 1.5 billion (USD 220 million) to address capacity constraints and support new product industrialization.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65221#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=65221\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65221#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Shenzhen Weiguang Biological to Raise RMB 1.5B in Private Placement to Fund Smart Industrial Base Expansion\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Shenzhen Weiguang Biological to Raise RMB 1.5B in Private Placement to Fund Smart Industrial Base Expansion - Insight, China&#039;s Pharmaceutical Industry","description":"Shenzhen Weiguang Biological Products Co., Ltd. (SHE: 002880), a China-based blood products manufacturer, announced plans to issue A-shares to specific targeted investors in a private placement aiming to raise RMB 1.5 billion (USD 220 million) to address capacity constraints and support new product industrialization.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=65221","og_locale":"en_US","og_type":"article","og_title":"Shenzhen Weiguang Biological to Raise RMB 1.5B in Private Placement to Fund Smart Industrial Base Expansion","og_description":"Shenzhen Weiguang Biological Products Co., Ltd. (SHE: 002880), a China-based blood products manufacturer, announced plans to issue A-shares to specific targeted investors in a private placement aiming to raise RMB 1.5 billion (USD 220 million) to address capacity constraints and support new product industrialization.","og_url":"https:\/\/flcube.com\/?p=65221","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-05-13T15:32:00+00:00","article_modified_time":"2026-05-13T15:32:03+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=65221#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=65221"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Shenzhen Weiguang Biological to Raise RMB 1.5B in Private Placement to Fund Smart Industrial Base Expansion","datePublished":"2026-05-13T15:32:00+00:00","dateModified":"2026-05-13T15:32:03+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=65221"},"wordCount":586,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["SHE: 002880","Weiguang Biological Products"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=65221#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=65221","url":"https:\/\/flcube.com\/?p=65221","name":"Shenzhen Weiguang Biological to Raise RMB 1.5B in Private Placement to Fund Smart Industrial Base Expansion - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-05-13T15:32:00+00:00","dateModified":"2026-05-13T15:32:03+00:00","description":"Shenzhen Weiguang Biological Products Co., Ltd. (SHE: 002880), a China-based blood products manufacturer, announced plans to issue A-shares to specific targeted investors in a private placement aiming to raise RMB 1.5 billion (USD 220 million) to address capacity constraints and support new product industrialization.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=65221#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=65221"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=65221#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Shenzhen Weiguang Biological to Raise RMB 1.5B in Private Placement to Fund Smart Industrial Base Expansion"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65221","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=65221"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65221\/revisions"}],"predecessor-version":[{"id":65223,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65221\/revisions\/65223"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=65221"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=65221"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=65221"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}